Lenalidomide decreased the PSA level for castration-resistant prostate cancer: a case report.
Clin Case Rep
; 6(2): 391-394, 2018 02.
Article
in En
| MEDLINE
| ID: mdl-29445483
ABSTRACT
Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration-resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Clin Case Rep
Year:
2018
Document type:
Article